Just five months after Novartis put down $310 million for IFM Therapeutics’ inflammation-focused unit, the Big Pharma has come back for more. This time, it is teaming up with IFM Due, the subsidiary IFM created to develop treatments targeting the cGAS and STING pathways, with an exclusive buyout option worth up to $840 million.
One of the joys of building a company is that meeting one’s milestones routinely places us in positions that are new, where past experience may not be a guide. Our ability to navigate growth is highly dependent on building a team that’s ready to take on increasing complexity.
This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC.
The startup paradigm for the creation and funding of new biotech companies has evolved enormously over the past two decades. Recently there’s been a pair of articles from Tech VCs about applying alternative models of company creation (here, here) to the world of biotech, so thought it was worth reflecting on the prevailing venture formation landscape and offering up some counterpoints.
New therapeutic platforms, like those based on cell and gene therapy, provide potential to address diseases in new ways and hold tremendous promise for alleviating human suffering. Despite this, progress often reaches a critical juncture when attempts are made to scale manufacturing from research to late-stage clinical trials and commercialization.
This blog was written by Aoife Brennan, CEO of Synlogic Therapeutics, as part of the From The Trenches feature of LifeSciVC.
Some of the most promising and innovative research underlying biotech start-ups arises in research institutions. It is often with those very institutions that we can best collaborate to advance such innovations. Academic researchers are insightful scientific advisors in new areas of biology and are poised to assist in important, thoughtful breakthroughs in ways that contract research organization (CRO) researchers sometimes are not.
This blog was written by Samantha Truex, Atlas EIR and CEO of Quench Bio, as part of the From The Trenches feature of LifeSciVC.